Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Robert W. Beart"'
Autor:
Parkash S. Gill, Michael Kahn, Cu Nguyen, Gagandeep Singh, Robert W. Beart, Fred A. Weaver, Debra Hawes, Robert D. Ladner, Parmeet K. Manchanda, Ren Liu, Valery Krasnoperov, Jasbir Singh, Eric J. Ley, Jeffrey S. Scehnet, S. Ram Kumar
The receptor tyrosine kinase EphB2 is expressed by colon progenitor cells; however, only 39% of colorectal tumors express EphB2 and expression levels decline with disease progression. Conversely, EphB4 is absent in normal colon but is expressed in al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::640e021d9da0a19569a14309128c6a56
https://doi.org/10.1158/0008-5472.c.6499827.v1
https://doi.org/10.1158/0008-5472.c.6499827.v1
Autor:
Parkash S. Gill, Michael Kahn, Cu Nguyen, Gagandeep Singh, Robert W. Beart, Fred A. Weaver, Debra Hawes, Robert D. Ladner, Parmeet K. Manchanda, Ren Liu, Valery Krasnoperov, Jasbir Singh, Eric J. Ley, Jeffrey S. Scehnet, S. Ram Kumar
Supplementary Methods and Figure Legends 1-11 from Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer Progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d671145957b039f435b42ad3255c63
https://doi.org/10.1158/0008-5472.22381296.v1
https://doi.org/10.1158/0008-5472.22381296.v1
Autor:
Parkash S. Gill, Michael Kahn, Cu Nguyen, Gagandeep Singh, Robert W. Beart, Fred A. Weaver, Debra Hawes, Robert D. Ladner, Parmeet K. Manchanda, Ren Liu, Valery Krasnoperov, Jasbir Singh, Eric J. Ley, Jeffrey S. Scehnet, S. Ram Kumar
Supplementary Figures 1-11 from Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer Progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cec7c82ba1474ed6d80f609e2c1151f
https://doi.org/10.1158/0008-5472.22381299.v1
https://doi.org/10.1158/0008-5472.22381299.v1
Autor:
Patricia A. Ganz, Marian Hemmelgarn, Michael J. O'Connell, Marcia M. Russell, Formosa C. Chen, Linda H. Colangelo, Robert W. Beart, Shonan Sho, Greg Yothers, Clifford Y. Ko
Publikováno v:
Dis Colon Rectum
BACKGROUND Accurate and comprehensive surgical pathology reports are integral to the quality of cancer care. Despite guidelines from the College of American Pathologists, variations in reporting quality continue to exist. OBJECTIVE The aim of this st
Autor:
Robert W. Beart
Publikováno v:
Diseases of the colon and rectum. 62(12)
Autor:
Robert W. Beart
Publikováno v:
Diseases of the colon and rectum. 60(5)
Autor:
Noam Avraham VanderWalde, Jennifer Moughan, Stuart M. Lichtman, Reshma Jagsi, Matthew T. Ballo, Ari M. Vanderwalde, Mohammed Mohiuddin, Neal J. Meropol, Lisa A. Kachnic, Michael C. Garofalo, Jaffer A. Ajani, Robert W. Beart, Rani Anne, Lisa Smith Evans, Amit Arora, Joshua E. Meyer, James J. Lee, John A. Keech, Gamini S. Soori, Christopher H. Crane
Publikováno v:
Journal of Clinical Oncology. 37:649-649
649 Background: This study sought to compare adverse events (AEs) of older and younger adults with lower gastrointestinal (GI) malignancies treated on NRG studies. Methods: Data from six NRG trials (RTOG 9811/0012/0247/0529/0822 & NSABP R-04), testin
Publikováno v:
Diseases of the Colon & Rectum. 53:713-720
Purpose The surgical workforce within the United States is moving rapidly toward increasing subspecialization. We hypothesized that over time an increasing proportion of colorectal procedures is performed by subspecialty-trained colorectal surgeons.
Publikováno v:
Journal of Clinical Oncology. 28:1175-1180
Purpose In choosing the appropriate surgical option for patients with colon cancer and Lynch syndrome, goals of treatment are to maximize life expectancy while preserving quality of life. This study constructs a decision model that encompasses these
Publikováno v:
The American Surgeon. 75:976-980
The treatment costs for patients in the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-α, has been extensively used to treat IBD, with 390,000 IBD patients receiv